Marta Artola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3856730/publications.pdf Version: 2024-02-01



Μλατλ Δατοιλ

#	Article	IF	CITATIONS
1	Consequences of excessive glucosylsphingosine in glucocerebrosidase-deficient zebrafish Journal of Lipid Research, 2022, , 100199.	2.0	9
2	Human glucocerebrosidase mediates formation of xylosyl-cholesterol by β-xylosidase and transxylosidase reactions. Journal of Lipid Research, 2021, 62, 100018.	2.0	5
3	Activity-Based Protein Profiling of Retaining α-Amylases in Complex Biological Samples. Journal of the American Chemical Society, 2021, 143, 2423-2432.	6.6	17
4	Cysteine Nucleophiles in Glycosidase Catalysis: Application of a Covalent βâ€ <scp>lâ€</scp> Arabinofuranosidase Inhibitor. Angewandte Chemie - International Edition, 2021, 60, 5754-5758.	7.2	16
5	Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions. Biomolecules, 2021, 11, 271.	1.8	50
6	Cysteine Nucleophiles in Glycosidase Catalysis: Application of a Covalent βâ€ <scp>lâ€</scp> Arabinofuranosidase Inhibitor. Angewandte Chemie, 2021, 133, 5818-5822.	1.6	3
7	Targeting the FtsZ Allosteric Binding Site with a Novel Fluorescence Polarization Screen, Cytological and Structural Approaches for Antibacterial Discovery. Journal of Medicinal Chemistry, 2021, 64, 5730-5745.	2.9	11
8	Xyloseâ€Configured Cyclophellitols as Selective Inhibitors for Glucocerebrosidase. ChemBioChem, 2021, 22, 3090-3098.	1.3	4
9	Design, Synthesis and Structural Analysis of Glucocerebrosidase Imaging Agents. Chemistry - A European Journal, 2021, 27, 16377-16388.	1.7	7
10	Discovering the Microbial Enzymes Driving Drug Toxicity with Activity-Based Protein Profiling. ACS Chemical Biology, 2020, 15, 217-225.	1.6	46
11	Rational Design of Mechanism-Based Inhibitors and Activity-Based Probes for the Identification of Retaining α- <scp>l</scp> -Arabinofuranosidases. Journal of the American Chemical Society, 2020, 142, 4648-4662.	6.6	33
12	Plant Glycosides and Glycosidases: A Treasure-Trove for Therapeutics. Frontiers in Plant Science, 2020, 11, 357.	1.7	63
13	Structure of a GH51 α- <scp>L</scp> -arabinofuranosidase from <i>Meripilus giganteus</i> : conserved substrate recognition from bacteria to fungi. Acta Crystallographica Section D: Structural Biology, 2020, 76, 1124-1133.	1.1	8
14	An overview of activity-based probes for glycosidases. Current Opinion in Chemical Biology, 2019, 53, 25-36.	2.8	76
15	α- <scp>d</scp> -Gal-cyclophellitol cyclosulfamidate is a Michaelis complex analog that stabilizes therapeutic lysosomal α-galactosidase A in Fabry disease. Chemical Science, 2019, 10, 9233-9243.	3.7	11
16	Functionalized Cyclophellitols Are Selective Glucocerebrosidase Inhibitors and Induce a Bona Fide Neuropathic Gaucher Model in Zebrafish. Journal of the American Chemical Society, 2019, 141, 4214-4218.	6.6	28
17	Role of μ-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish. Journal of Lipid Research, 2019, 60, 1851-1867.	2.0	29
18	Glycosphingolipids and lysosomal storage disorders as illustrated by gaucher disease. Current Opinion in Chemical Biology, 2019, 53, 204-215.	2.8	38

MARTA ARTOLA

#	Article	IF	CITATIONS
19	Direct Stereoselective Aziridination of Cyclohexenols with 3â€Aminoâ€2â€{trifluoromethyl)quinazolinâ€4(3 <i>H</i>)â€one in the Synthesis of Cyclitol Aziridine Glycosidase Inhibitors. European Journal of Organic Chemistry, 2019, 2019, 1397-1404.	e 1.2	5
20	<i>InÂvivo</i> inactivation of glycosidases by conduritol B epoxide and cyclophellitol as revealed by activityâ€based protein profiling. FEBS Journal, 2019, 286, 584-600.	2.2	44
21	Nicotiana benthamiana α-galactosidase A1.1 can functionally complement human α-galactosidase A deficiency associated with Fabry disease. Journal of Biological Chemistry, 2018, 293, 10042-10058.	1.6	20
22	Activity-Based Probes for Glycosidases: Profiling and Other Applications. Methods in Enzymology, 2018, 598, 217-235.	0.4	21
23	Gluco-1 <i>H</i> -imidazole: A New Class of Azole-Type β-Glucosidase Inhibitor. Journal of the American Chemical Society, 2018, 140, 5045-5048.	6.6	17
24	New Irreversible αâ€ <scp>l</scp> â€lduronidase Inhibitors and Activityâ€Based Probes. Chemistry - A European Journal, 2018, 24, 19081-19088.	1.7	9
25	Distinguishing the differences in β-glycosylceramidase folds, dynamics, and actions informs therapeutic uses. Journal of Lipid Research, 2018, 59, 2262-2276.	2.0	12
26	Carba-cyclophellitols Are Neutral Retaining-Glucosidase Inhibitors. Journal of the American Chemical Society, 2017, 139, 6534-6537.	6.6	24
27	Novel activity-based probes for N-acylethanolamine acid amidase. Chemical Communications, 2017, 53, 11810-11813.	2.2	7
28	Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs. ACS Central Science, 2017, 3, 1276-1285.	5.3	47
29	Towards broad spectrum activity-based glycosidase probes: synthesis and evaluation of deoxygenated cyclophellitol aziridines. Chemical Communications, 2017, 53, 12528-12531.	2.2	27
30	1,6-Cyclophellitol Cyclosulfates: A New Class of Irreversible Glycosidase Inhibitor. ACS Central Science, 2017, 3, 784-793.	5.3	43
31	The structural assembly switch of cell division protein FtsZ probed with fluorescent allosteric inhibitors. Chemical Science, 2017, 8, 1525-1534.	3.7	33
32	Activity-based probes for functional interrogation of retaining β-glucuronidases. Nature Chemical Biology, 2017, 13, 867-873.	3.9	76
33	The Synthesis of Cyclophellitolâ€Aziridine and Its Configurational and Functional Isomers. European Journal of Organic Chemistry, 2016, 2016, 3671-3678.	1.2	14
34	A Divergent Synthesis of <scp>l</scp> â€ <i>arabino</i> ―and <scp>d</scp> â€ <i>xylo</i> onfigured Cyclophellitol Epoxides and Aziridines. European Journal of Organic Chemistry, 2016, 2016, 4787-4794.	1.2	19
35	Identification of a Novel Orally Bioavailable Phosphodiesterase 10A (PDE10A) Inhibitor with Efficacy in Animal Models of Schizophrenia Journal of Medicinal Chemistry, 2015, 58, 978-993.	2.9	16
36	Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer. Journal of the National Cancer Institute, 2015, 107, djv077.	3.0	98

#	Article	IF	CITATIONS
37	Effective GTP-Replacing FtsZ Inhibitors and Antibacterial Mechanism of Action. ACS Chemical Biology, 2015, 10, 834-843.	1.6	25
38	Synthetic Inhibitors of Bacterial Cell Division Targeting the GTP-Binding Site of FtsZ. ACS Chemical Biology, 2013, 8, 2072-2083.	1.6	52
39	New Synthetic Inhibitors of Fatty Acid Synthase with Anticancer Activity. Journal of Medicinal Chemistry, 2012, 55, 5013-5023.	2.9	57